

Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 – 5th Interim Announcement

In the period from January 30, 2023 up to and including February 03, 2023, PharmaSGP Holding SE bought back a total of 385 shares of PharmaSGP Holding SE under the share buyback program; on January 3, 2023, PharmaSGP Holding SE disclosed pursuant to Art. 2 Sec. 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on January 4, 2023.

The overall volume of the shares bought back daily in the period from January 30, 2023 up to and including February 03, 2023 and the daily volume-weighted average stock market prices of the shares are as follows:

Date	Aggregate volume	Weighted average price (EUR)
January 30, 2023	40	25.8000
January 31, 2023	120	25.8000
February 01, 2023	125	25.4600
February 02, 2023	-	-
February 03, 2023	100	25.8000
In total	385	25.6896

The total number of shares which have been bought back under the buyback program from January 4, 2023 up to and including February 03, 2023 thus amounts to 1704 shares.

The purchase of the PharmaSGP Holding SE shares was carried out by a bank commissioned by PharmaSGP Holding SE and exclusively via the Frankfurt Stock Exchange (XETRA trading).

More detailed information pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available on the internet at <https://ir.pharmasgp.com> at share buyback 2023.

Gräfelfing, February 06, 2023

PharmaSGP Holding SE
The Management Board